| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/15412555.2017.1303041 |
| P698 | PubMed publication ID | 28388265 |
| P50 | author | Alexandru Corlateanu | Q59829744 |
| P2093 | author name string | Nikolaos Siafakas | |
| Evangelia Fouka | |||
| P2860 | cites work | Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function | Q24633262 |
| Chronic bronchitis and chronic obstructive pulmonary disease | Q26991702 | ||
| New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives | Q27024384 | ||
| A review of national guidelines for management of COPD in Europe | Q28072014 | ||
| Histone acetylation and deacetylation: importance in inflammatory lung diseases | Q28237379 | ||
| Genome-wide association study of smoking behaviours in patients with COPD | Q29417072 | ||
| Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper | Q29614960 | ||
| DNA methylation and human disease | Q29615417 | ||
| Derivation and validation of clinical phenotypes for COPD: a systematic review. | Q30653887 | ||
| Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials | Q30933471 | ||
| A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. | Q33419815 | ||
| The exposome: a new paradigm to study the impact of environment on health | Q33441100 | ||
| BODE-Index vs HADO-score in chronic obstructive pulmonary disease: Which one to use in general practice? | Q33585772 | ||
| Variants in FAM13A are associated with chronic obstructive pulmonary disease | Q33687879 | ||
| Characterisation of COPD heterogeneity in the ECLIPSE cohort | Q34149510 | ||
| Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis | Q34198955 | ||
| Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype | Q34280020 | ||
| Genetic susceptibility for chronic bronchitis in chronic obstructive pulmonary disease | Q34309196 | ||
| An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. | Q38398677 | ||
| An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease | Q38399184 | ||
| Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD. | Q38412833 | ||
| Clinically relevant subgroups in COPD and asthma | Q38509902 | ||
| A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. | Q38753716 | ||
| Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema | Q39818948 | ||
| Chronic obstructive pulmonary disease phenotypes: the future of COPD. | Q39867138 | ||
| Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. | Q40753167 | ||
| Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease | Q44077968 | ||
| Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes | Q44406271 | ||
| Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice | Q44984821 | ||
| Pulmonary function and sputum characteristics predict computed tomography phenotype and severity of COPD. | Q45927617 | ||
| Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. | Q47607188 | ||
| Chronic obstructive pulmonary disease: thin-section CT measurement of airway wall thickness and lung attenuation. | Q47860012 | ||
| Distinct clinical phenotypes of airways disease defined by cluster analysis. | Q48672796 | ||
| Eosinophilic inflammation in COPD: prevalence and clinical characteristics. | Q50458300 | ||
| Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. | Q50697152 | ||
| Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. | Q50792764 | ||
| Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. | Q51159286 | ||
| Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. | Q51171610 | ||
| The rapid FEV(1) decline in chronic obstructive pulmonary disease is associated with predominant emphysema: a longitudinal study. | Q53126886 | ||
| Involvement of endothelial apoptosis underlying chronic obstructive pulmonary disease-like phenotype in adiponectin-null mice: implications for therapy. | Q54619726 | ||
| Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease | Q57955696 | ||
| Chronic Obstructive Pulmonary Disease Biomarker(s) for Disease Activity Needed—Urgently | Q57955794 | ||
| Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease | Q57955820 | ||
| Preparing for Precision Medicine | Q58045547 | ||
| Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation | Q58840455 | ||
| From COPD to chronic systemic inflammatory syndrome? | Q58877168 | ||
| Genome-wide association identifies regulatory Loci associated with distinct local histogram emphysema patterns | Q34425983 | ||
| Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease | Q34535065 | ||
| The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease | Q34546085 | ||
| Tiotropium Respimat inhaler and the risk of death in COPD. | Q34655749 | ||
| Few smokers develop COPD. Why? | Q34796703 | ||
| Clinical practice. Alpha1-antitrypsin deficiency | Q34988812 | ||
| IREB2 and GALC are associated with pulmonary artery enlargement in chronic obstructive pulmonary disease | Q35207735 | ||
| Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes | Q35249531 | ||
| Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease | Q35530899 | ||
| Azithromycin for prevention of exacerbations of COPD. | Q35564000 | ||
| A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. | Q35816887 | ||
| Effect of five genetic variants associated with lung function on the risk of chronic obstructive lung disease, and their joint effects on lung function | Q36099476 | ||
| Laboratory markers for COPD in "susceptible" smokers | Q36247944 | ||
| The role of heme oxygenase-1 in pulmonary disease | Q36330628 | ||
| DNA damage due to oxidative stress in Chronic Obstructive Pulmonary Disease (COPD) | Q36538520 | ||
| Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. | Q36907742 | ||
| Phenotypes of chronic obstructive pulmonary disease | Q37008634 | ||
| Factors associated with change in exacerbation frequency in COPD | Q37071132 | ||
| Immunologic aspects of chronic obstructive pulmonary disease | Q37506948 | ||
| Current perspectives on role of chromatin modifications and deacetylases in lung inflammation in COPD. | Q37610467 | ||
| Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease | Q37653480 | ||
| Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine | Q37822219 | ||
| Systemic manifestations of COPD. | Q37826279 | ||
| Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease | Q37836078 | ||
| Clinical phenotypes of COPD: identification, definition and implications for guidelines | Q37971123 | ||
| How to integrate multiple comorbidities in guideline development: article 10 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report | Q38068890 | ||
| Immune and genetic mechanisms in COPD: possible targets for therapeutic interventions | Q38068941 | ||
| Variations in FEV₁ decline over time in chronic obstructive pulmonary disease and its implications | Q38071459 | ||
| Oxidative stress in COPD. | Q38123637 | ||
| Lessons from ECLIPSE: a review of COPD biomarkers | Q38169066 | ||
| Phenotypes and disease characterization in chronic obstructive pulmonary disease. Toward the extinction of phenotypes? | Q38169240 | ||
| The path to personalised medicine in COPD. | Q38208185 | ||
| Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. | Q38245605 | ||
| Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression | Q38317463 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 367-374 | |
| P577 | publication date | 2017-04-07 | |
| P1433 | published in | COPD: Journal of Chronic Obstructive Pulmonary Disease | Q5013430 |
| P1476 | title | Phenotyping Before Starting Treatment in COPD? | |
| P478 | volume | 14 |
| Q96953110 | Paraoxonase Activity and Phenotype Distribution in Patients with Chronic Obstructive Pulmonary Disease |
| Q55120067 | Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD. |
| Q92116005 | Review of Drug Development Guidance to Treat Chronic Obstructive Pulmonary Disease: US and EU Perspectives |
| Q64950994 | Treatment of COPD: the simplicity is a resolved complexity. |
Search more.